Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 2/20 | 0.33 |
| ▸ | CNR2 | P34972 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16445658 | 0.90 | HPGD (0.30) | — | |
| SCHEMBL2797934 | 0.82 | PRKAB2 (0.32) | — | |
| SCHEMBL20730381 | 0.75 | HPGD (0.32) | — | |
| SCHEMBL15831730 | 0.72 | CDK8 (0.33) | ALDH1A1 | |
| SCHEMBL234891 | 0.72 | HPGD (0.44) | ALDH1A1 | |
| SCHEMBL22164238 | 0.70 | LMNA (0.31) | — | |
| SCHEMBL9713237 | 0.69 | HPGD (0.33) | — | |
| SCHEMBL9713657 | 0.66 | LMNA (0.30) | ALDH1A1 | |
| SCHEMBL21847663 | 0.63 | JAK2 (0.32) | — | |
| SCHEMBL22164239 | 0.62 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265075-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | AJAX THERAPEUTICS, INC. | 2023-08-24 | — | — | US | disclosed |
| US-20230265075-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | AJAX THERAPEUTICS, INC. | 2023-08-24 | — | — | US | disclosed |
| US-11691963-B2 | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors | AJAX THERAPEUTICS, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| US-11691963-B2 | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors | AJAX THERAPEUTICS, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| WO-2023009712-A1 | HETEROARYLOXY THIAZOLO AZINES AS JAK2 INHIBITORS | AJAX THERAPEUTICS, INC. (US) | 2023-02-02 | — | — | WO | disclosed |
| WO-2023009709-A1 | PYRAZOLO PIPERAZINES AS JAK2 INHIBITORS | AJAX THERAPEUTICS, INC. (US) | 2023-02-02 | — | — | WO | disclosed |
| WO-2023009708-A1 | HETEROARYLOXY TRIAZOLO- AND IMIDAZO-AZINES AS JAK2 INHIBITORS | AJAX THERAPEUTICS, INC. (US) | 2023-02-02 | — | — | WO | disclosed |
| US-20220411403-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | AJAX THERAPEUTICS, INC. | 2022-12-29 | — | — | US | disclosed |
| WO-2022140527-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | AJAX THERAPEUTICS, INC. (US) | 2022-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220411403-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | JAK2, JAK3, STAT5B | CNR1 4118/4885CNR2 3981/4885ALDH1A1 3735/4885 |
| US-20230265075-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | JAK2, JAK3, STAT5B | CNR1 4118/4885CNR2 3981/4885ALDH1A1 3735/4885 |
| US-11691963-B2 | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors | JAK2, JAK3, STAT5B | CNR1 4118/4885CNR2 3981/4885ALDH1A1 3735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.